Financing ·
Inovio Pharmaceuticals entered into an underwriting agreement on July 29, 2026, to sell 21,052,632 shares of common…
INOInovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals entered into an underwriting agreement on July 29, 2026, to sell 21,052,632 shares of common stock and accompanying warrants in a public offering. The securities were priced at $0.95 per share and warrant combination, with the warrants exercisable for two additional shares at $1.10 per share. Gross proceeds are expected to be approximately $20.0 million, netting roughly $18.3 million after underwriting discounts and expenses. The company granted Piper Sandler & Co. a 30-day option to purchase up to 15% additional securities, which was exercised for warrants only. Closing is anticipated on or about July 31, 2026. Inovio Pharmaceuticals operates in the biotechnology industry, focusing on developing and commercializing DNA medicines.